Anti-PD-1 antibodies in melanoma

Article Type
Changed
Fri, 01/04/2019 - 11:08
Display Headline
Anti-PD-1 antibodies in melanoma

The programmed death 1 (PD-1) receptor is a negative regulator of T-cell effector mechanisms that limits immune responses against cancer. Two recent phase 1 studies of anti-PD-1 antibodies indicate that these agents exhibit considerable antitumor activity alone or in combination with ipilimumab in patients with advanced melanoma.

*Click on the links to the left for PDFs of the full article and related Commentary.

Article PDF
Author and Disclosure Information

Publications
Topics
Legacy Keywords
melanoma, lambrolizumab, nivolumab, ipilimumab
Author and Disclosure Information

Author and Disclosure Information

Article PDF
Article PDF

The programmed death 1 (PD-1) receptor is a negative regulator of T-cell effector mechanisms that limits immune responses against cancer. Two recent phase 1 studies of anti-PD-1 antibodies indicate that these agents exhibit considerable antitumor activity alone or in combination with ipilimumab in patients with advanced melanoma.

*Click on the links to the left for PDFs of the full article and related Commentary.

The programmed death 1 (PD-1) receptor is a negative regulator of T-cell effector mechanisms that limits immune responses against cancer. Two recent phase 1 studies of anti-PD-1 antibodies indicate that these agents exhibit considerable antitumor activity alone or in combination with ipilimumab in patients with advanced melanoma.

*Click on the links to the left for PDFs of the full article and related Commentary.

Publications
Publications
Topics
Article Type
Display Headline
Anti-PD-1 antibodies in melanoma
Display Headline
Anti-PD-1 antibodies in melanoma
Legacy Keywords
melanoma, lambrolizumab, nivolumab, ipilimumab
Legacy Keywords
melanoma, lambrolizumab, nivolumab, ipilimumab
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

BTK inhibitor ibrutinib in CLL and mantle cell lymphoma

Article Type
Changed
Thu, 03/28/2019 - 15:57
Display Headline
BTK inhibitor ibrutinib in CLL and mantle cell lymphoma

Bruton’s tyrosine kinase (BTK) is a critical component of B-cell–receptor signaling that mediates interactions with the tumor microenvironment and promotes survival and proliferation of chronic lymphocytic leukemia (CLL) cells. Ibrutinib is a first-in-class oral covalent inhibitor of BTK designed for the treatment of B-cell cancers. In a phase 1b/2 study reported by Byrd and colleagues, ibrutinib treatment was found to produce high rates of durable responses in patients with relapsed or refractory CLL or small lymphocytic lymphoma.1

 
*Click on the links to the left for PDFs of the full article and related Commentary.

Article PDF
Author and Disclosure Information

Publications
Topics
Legacy Keywords
BTK inhibitor, ibrutinib, chronic lymphocytic leukemia, CLL, mantle cell lymphoma
Author and Disclosure Information

Author and Disclosure Information

Article PDF
Article PDF

Bruton’s tyrosine kinase (BTK) is a critical component of B-cell–receptor signaling that mediates interactions with the tumor microenvironment and promotes survival and proliferation of chronic lymphocytic leukemia (CLL) cells. Ibrutinib is a first-in-class oral covalent inhibitor of BTK designed for the treatment of B-cell cancers. In a phase 1b/2 study reported by Byrd and colleagues, ibrutinib treatment was found to produce high rates of durable responses in patients with relapsed or refractory CLL or small lymphocytic lymphoma.1

 
*Click on the links to the left for PDFs of the full article and related Commentary.

Bruton’s tyrosine kinase (BTK) is a critical component of B-cell–receptor signaling that mediates interactions with the tumor microenvironment and promotes survival and proliferation of chronic lymphocytic leukemia (CLL) cells. Ibrutinib is a first-in-class oral covalent inhibitor of BTK designed for the treatment of B-cell cancers. In a phase 1b/2 study reported by Byrd and colleagues, ibrutinib treatment was found to produce high rates of durable responses in patients with relapsed or refractory CLL or small lymphocytic lymphoma.1

 
*Click on the links to the left for PDFs of the full article and related Commentary.

Publications
Publications
Topics
Article Type
Display Headline
BTK inhibitor ibrutinib in CLL and mantle cell lymphoma
Display Headline
BTK inhibitor ibrutinib in CLL and mantle cell lymphoma
Legacy Keywords
BTK inhibitor, ibrutinib, chronic lymphocytic leukemia, CLL, mantle cell lymphoma
Legacy Keywords
BTK inhibitor, ibrutinib, chronic lymphocytic leukemia, CLL, mantle cell lymphoma
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Chimeric antigen receptor-modified T cells in acute lymphoblastic leukemia

Article Type
Changed
Thu, 03/28/2019 - 15:58
Display Headline
Chimeric antigen receptor-modified T cells in acute lymphoblastic leukemia

Recent studies have documented the ability of chimeric antigen receptor-modified autologous T cells targeting the CD19 antigen on B cells to induce rapid and deep remissions in adult and pediatric patients with relapsed or refractory acute lymphoblastic leukemia (ALL).1,2

*Click on the links to the left for PDFs of the full article and related Commentary.
 

Article PDF
Author and Disclosure Information

Publications
Topics
Legacy Keywords
chimeric antigen receptor, CARS, T cells, acute lymphoblastic leukemia, ALL
Author and Disclosure Information

Author and Disclosure Information

Article PDF
Article PDF

Recent studies have documented the ability of chimeric antigen receptor-modified autologous T cells targeting the CD19 antigen on B cells to induce rapid and deep remissions in adult and pediatric patients with relapsed or refractory acute lymphoblastic leukemia (ALL).1,2

*Click on the links to the left for PDFs of the full article and related Commentary.
 

Recent studies have documented the ability of chimeric antigen receptor-modified autologous T cells targeting the CD19 antigen on B cells to induce rapid and deep remissions in adult and pediatric patients with relapsed or refractory acute lymphoblastic leukemia (ALL).1,2

*Click on the links to the left for PDFs of the full article and related Commentary.
 

Publications
Publications
Topics
Article Type
Display Headline
Chimeric antigen receptor-modified T cells in acute lymphoblastic leukemia
Display Headline
Chimeric antigen receptor-modified T cells in acute lymphoblastic leukemia
Legacy Keywords
chimeric antigen receptor, CARS, T cells, acute lymphoblastic leukemia, ALL
Legacy Keywords
chimeric antigen receptor, CARS, T cells, acute lymphoblastic leukemia, ALL
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Enzalutamide in castrate-resistant prostate cancer after chemotherapy

Article Type
Changed
Fri, 01/04/2019 - 11:07
Display Headline
Enzalutamide in castrate-resistant prostate cancer after chemotherapy

Enzalutamide is an androgen receptor-signaling inhibitor that is reported to differ from conventional antiandrogen agents in that it inhibits androgen receptor nuclear translocation, DNA binding, and coactivator recruitment; exhibits increased affinity for the androgen receptor; and induces tumor reduction, rather than slowing growth, in preclinical models. The recently reported AFFIRM study showed that enzalutamide treatment after chemotherapy significantly prolonged overall survival (OS), radiographic progression-free survival (PFS), time to prostate-specific antigen (PSA) progression, and time to skeletal-related events (SREs) in men with castration-resistant prostate cancer. This trial formed the basis for the recent approval of enzalutamide for the treatment of patients with metastatic castrationresistant prostate cancer who have previously received docetaxel.

*Click on the links to the left for PDFs of the full article and related Commentary.  

Article PDF
Author and Disclosure Information

Publications
Topics
Legacy Keywords
enzalutamide, castrate-resistant prostate cancer, AFFIRM trial, CRPC

Author and Disclosure Information

Author and Disclosure Information

Article PDF
Article PDF

Enzalutamide is an androgen receptor-signaling inhibitor that is reported to differ from conventional antiandrogen agents in that it inhibits androgen receptor nuclear translocation, DNA binding, and coactivator recruitment; exhibits increased affinity for the androgen receptor; and induces tumor reduction, rather than slowing growth, in preclinical models. The recently reported AFFIRM study showed that enzalutamide treatment after chemotherapy significantly prolonged overall survival (OS), radiographic progression-free survival (PFS), time to prostate-specific antigen (PSA) progression, and time to skeletal-related events (SREs) in men with castration-resistant prostate cancer. This trial formed the basis for the recent approval of enzalutamide for the treatment of patients with metastatic castrationresistant prostate cancer who have previously received docetaxel.

*Click on the links to the left for PDFs of the full article and related Commentary.  

Enzalutamide is an androgen receptor-signaling inhibitor that is reported to differ from conventional antiandrogen agents in that it inhibits androgen receptor nuclear translocation, DNA binding, and coactivator recruitment; exhibits increased affinity for the androgen receptor; and induces tumor reduction, rather than slowing growth, in preclinical models. The recently reported AFFIRM study showed that enzalutamide treatment after chemotherapy significantly prolonged overall survival (OS), radiographic progression-free survival (PFS), time to prostate-specific antigen (PSA) progression, and time to skeletal-related events (SREs) in men with castration-resistant prostate cancer. This trial formed the basis for the recent approval of enzalutamide for the treatment of patients with metastatic castrationresistant prostate cancer who have previously received docetaxel.

*Click on the links to the left for PDFs of the full article and related Commentary.  

Publications
Publications
Topics
Article Type
Display Headline
Enzalutamide in castrate-resistant prostate cancer after chemotherapy
Display Headline
Enzalutamide in castrate-resistant prostate cancer after chemotherapy
Legacy Keywords
enzalutamide, castrate-resistant prostate cancer, AFFIRM trial, CRPC

Legacy Keywords
enzalutamide, castrate-resistant prostate cancer, AFFIRM trial, CRPC

Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Bosutinib in previously treated CML and in first-line comparison with imatinib

Article Type
Changed
Fri, 01/04/2019 - 11:07
Display Headline
Bosutinib in previously treated CML and in first-line comparison with imatinib

Bosutinib was recently approved for the treatment of chronic phase (CP), accelerated phase (AP), or blast phase (BP) Philadelphia chromosomepositive (Ph+) chronic myeloid leukemia (CML) in adult patients with resistance or intolerance to prior therapy. The approval was based on findings in a combined phase 1/2 single-arm trial.1 The recently reported phase 3 BELA trial compared bosutinib and imatinib as first-line treatments in patients with CP CML and reported no difference in complete cytogenetic response (CCyR) rates at 1 year, but improved major molecular response (MMR) rate and time to response, as well as a distinct safety profile.2


*Click on the links to the left for PDFs of the full article and related Commentary.

Article PDF
Author and Disclosure Information

Publications
Topics
Legacy Keywords
chronic myeloid leukemia, bosutinib, tyrosine kinase inhibitor, BELA trial,
Author and Disclosure Information

Author and Disclosure Information

Article PDF
Article PDF

Bosutinib was recently approved for the treatment of chronic phase (CP), accelerated phase (AP), or blast phase (BP) Philadelphia chromosomepositive (Ph+) chronic myeloid leukemia (CML) in adult patients with resistance or intolerance to prior therapy. The approval was based on findings in a combined phase 1/2 single-arm trial.1 The recently reported phase 3 BELA trial compared bosutinib and imatinib as first-line treatments in patients with CP CML and reported no difference in complete cytogenetic response (CCyR) rates at 1 year, but improved major molecular response (MMR) rate and time to response, as well as a distinct safety profile.2


*Click on the links to the left for PDFs of the full article and related Commentary.

Bosutinib was recently approved for the treatment of chronic phase (CP), accelerated phase (AP), or blast phase (BP) Philadelphia chromosomepositive (Ph+) chronic myeloid leukemia (CML) in adult patients with resistance or intolerance to prior therapy. The approval was based on findings in a combined phase 1/2 single-arm trial.1 The recently reported phase 3 BELA trial compared bosutinib and imatinib as first-line treatments in patients with CP CML and reported no difference in complete cytogenetic response (CCyR) rates at 1 year, but improved major molecular response (MMR) rate and time to response, as well as a distinct safety profile.2


*Click on the links to the left for PDFs of the full article and related Commentary.

Publications
Publications
Topics
Article Type
Display Headline
Bosutinib in previously treated CML and in first-line comparison with imatinib
Display Headline
Bosutinib in previously treated CML and in first-line comparison with imatinib
Legacy Keywords
chronic myeloid leukemia, bosutinib, tyrosine kinase inhibitor, BELA trial,
Legacy Keywords
chronic myeloid leukemia, bosutinib, tyrosine kinase inhibitor, BELA trial,
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Trastuzumab emtansine in advanced HER2-positive breast cancer

Article Type
Changed
Thu, 12/15/2022 - 18:18
Display Headline
Trastuzumab emtansine in advanced HER2-positive breast cancer

Trastuzumab emtansine is an antibody drug conjugate composed of trastuzumab (T) linked to a highly potent cytotoxic derivative of maytansine (DM1) by a stable linker (a nonreducible thioether, SMCC).1 DM1 binds to intracellular tubulin and prevents the assembly of microtubules, resulting in cell death. Trastuzumab targets the conjugate to the human epidermal growth factor receptor 2 (HER2) protein and the stable linker releases the cytotoxic agent only when the compound is internalized through receptor endocytosis. Trastuzumab emtansine (T-DM1) has been in found to be active in trastuzumab- and lapatinib-resistant disease, as well as in trastuzumab-naïve tumors...
 
*Click on the links to the left for PDFs of the full article and accompanying Commentary.

Article PDF
Author and Disclosure Information

Publications
Topics
Legacy Keywords
trastuzumab emtansine, HER2-positive breast cancer, T-DM1, EMILIA, MARIANNE trial, TH3RESA, antibody-drug conjugation, HR-positive breast cancer
Author and Disclosure Information

Author and Disclosure Information

Article PDF
Article PDF

Trastuzumab emtansine is an antibody drug conjugate composed of trastuzumab (T) linked to a highly potent cytotoxic derivative of maytansine (DM1) by a stable linker (a nonreducible thioether, SMCC).1 DM1 binds to intracellular tubulin and prevents the assembly of microtubules, resulting in cell death. Trastuzumab targets the conjugate to the human epidermal growth factor receptor 2 (HER2) protein and the stable linker releases the cytotoxic agent only when the compound is internalized through receptor endocytosis. Trastuzumab emtansine (T-DM1) has been in found to be active in trastuzumab- and lapatinib-resistant disease, as well as in trastuzumab-naïve tumors...
 
*Click on the links to the left for PDFs of the full article and accompanying Commentary.

Trastuzumab emtansine is an antibody drug conjugate composed of trastuzumab (T) linked to a highly potent cytotoxic derivative of maytansine (DM1) by a stable linker (a nonreducible thioether, SMCC).1 DM1 binds to intracellular tubulin and prevents the assembly of microtubules, resulting in cell death. Trastuzumab targets the conjugate to the human epidermal growth factor receptor 2 (HER2) protein and the stable linker releases the cytotoxic agent only when the compound is internalized through receptor endocytosis. Trastuzumab emtansine (T-DM1) has been in found to be active in trastuzumab- and lapatinib-resistant disease, as well as in trastuzumab-naïve tumors...
 
*Click on the links to the left for PDFs of the full article and accompanying Commentary.

Publications
Publications
Topics
Article Type
Display Headline
Trastuzumab emtansine in advanced HER2-positive breast cancer
Display Headline
Trastuzumab emtansine in advanced HER2-positive breast cancer
Legacy Keywords
trastuzumab emtansine, HER2-positive breast cancer, T-DM1, EMILIA, MARIANNE trial, TH3RESA, antibody-drug conjugation, HR-positive breast cancer
Legacy Keywords
trastuzumab emtansine, HER2-positive breast cancer, T-DM1, EMILIA, MARIANNE trial, TH3RESA, antibody-drug conjugation, HR-positive breast cancer
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Vismodegib in advanced basal cell carcinoma

Article Type
Changed
Fri, 01/04/2019 - 11:07
Display Headline
Vismodegib in advanced basal cell carcinoma

Vismodegib is an oral small-molecule inhibitor of smoothened homologue protein (SMO), a component of the hedgehog signaling pathway that has been shown to have activity in advanced basal cell carcinoma (BCC). In early 2012, vismodegib was approved by the Food and Drug Administration for treatment of adult patients with metastatic BCC (mBCC) who are not candidates for radiation therapy and adult patients with locally advanced BCC that has recurred following surgery or who are not candidates for surgery or radiation therapy1…

*Click on the links to the left of this introduction for a PDF of the full article and an accompanying Commentary.

Article PDF
Author and Disclosure Information

Publications
Topics
Author and Disclosure Information

Author and Disclosure Information

Article PDF
Article PDF

Vismodegib is an oral small-molecule inhibitor of smoothened homologue protein (SMO), a component of the hedgehog signaling pathway that has been shown to have activity in advanced basal cell carcinoma (BCC). In early 2012, vismodegib was approved by the Food and Drug Administration for treatment of adult patients with metastatic BCC (mBCC) who are not candidates for radiation therapy and adult patients with locally advanced BCC that has recurred following surgery or who are not candidates for surgery or radiation therapy1…

*Click on the links to the left of this introduction for a PDF of the full article and an accompanying Commentary.

Vismodegib is an oral small-molecule inhibitor of smoothened homologue protein (SMO), a component of the hedgehog signaling pathway that has been shown to have activity in advanced basal cell carcinoma (BCC). In early 2012, vismodegib was approved by the Food and Drug Administration for treatment of adult patients with metastatic BCC (mBCC) who are not candidates for radiation therapy and adult patients with locally advanced BCC that has recurred following surgery or who are not candidates for surgery or radiation therapy1…

*Click on the links to the left of this introduction for a PDF of the full article and an accompanying Commentary.

Publications
Publications
Topics
Article Type
Display Headline
Vismodegib in advanced basal cell carcinoma
Display Headline
Vismodegib in advanced basal cell carcinoma
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Regorafenib in previously treated metastatic colorectal cancer

Article Type
Changed
Wed, 05/26/2021 - 14:02
Display Headline
Regorafenib in previously treated metastatic colorectal cancer

The multikinase inhibitor regorafenib was recently approved for the treatment of patients with metastatic colorectal cancer (mCRC) who had been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-VEGF therapy, and, for patients with wild-type KRAS tumors, anti-EGFR therapy.1 Regorafenib inhibits numerous membrane-bound and intracellular kinases involved in normal cell function and in oncogenesis, tumor angiogenesis, and maintenance of the tumor microenvironment (including RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR- , PDGFR- , FGFR1, FGFR2, TIE2, DDR2, Trk2A, Eph2A, RAF-1, BRAF, BRAFV600E, SAPK2, PTK5, and Abl kinases). The approval was based on findings in the international, phase 3 CORRECT trial2

*Click on the links to the left of this introduction for a PDF of the full article and related Commentary.  

Article PDF
Author and Disclosure Information

Publications
Topics
Legacy Keywords
colorectal cancer, regorafenib, KRAS wild-type, multikinase inhibitor
Author and Disclosure Information

Author and Disclosure Information

Article PDF
Article PDF

The multikinase inhibitor regorafenib was recently approved for the treatment of patients with metastatic colorectal cancer (mCRC) who had been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-VEGF therapy, and, for patients with wild-type KRAS tumors, anti-EGFR therapy.1 Regorafenib inhibits numerous membrane-bound and intracellular kinases involved in normal cell function and in oncogenesis, tumor angiogenesis, and maintenance of the tumor microenvironment (including RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR- , PDGFR- , FGFR1, FGFR2, TIE2, DDR2, Trk2A, Eph2A, RAF-1, BRAF, BRAFV600E, SAPK2, PTK5, and Abl kinases). The approval was based on findings in the international, phase 3 CORRECT trial2

*Click on the links to the left of this introduction for a PDF of the full article and related Commentary.  

The multikinase inhibitor regorafenib was recently approved for the treatment of patients with metastatic colorectal cancer (mCRC) who had been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-VEGF therapy, and, for patients with wild-type KRAS tumors, anti-EGFR therapy.1 Regorafenib inhibits numerous membrane-bound and intracellular kinases involved in normal cell function and in oncogenesis, tumor angiogenesis, and maintenance of the tumor microenvironment (including RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR- , PDGFR- , FGFR1, FGFR2, TIE2, DDR2, Trk2A, Eph2A, RAF-1, BRAF, BRAFV600E, SAPK2, PTK5, and Abl kinases). The approval was based on findings in the international, phase 3 CORRECT trial2

*Click on the links to the left of this introduction for a PDF of the full article and related Commentary.  

Publications
Publications
Topics
Article Type
Display Headline
Regorafenib in previously treated metastatic colorectal cancer
Display Headline
Regorafenib in previously treated metastatic colorectal cancer
Legacy Keywords
colorectal cancer, regorafenib, KRAS wild-type, multikinase inhibitor
Legacy Keywords
colorectal cancer, regorafenib, KRAS wild-type, multikinase inhibitor
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Cetuximab plus FOLFIRI in first-line treatment of KRAS mutation-negative, EGFR-positive metastatic colorectal cancer

Article Type
Changed
Wed, 05/26/2021 - 14:03
Display Headline
Cetuximab plus FOLFIRI in first-line treatment of KRAS mutation-negative, EGFR-positive metastatic colorectal cancer


In July 2012, cetuximab was approved for use in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin) for first-line treatment of patients with KRAS mutation-negative (wild-type), EGFR-expressing metastatic colorectal cancer (mCRC) as determined by Food and Drug Administration-approved tests. A companion diagnostic, Therascreen KRAS RGQ PCR Kit for determining KRAS mutation status was approved concurrently with the cetuximab approval. The test is a real-time polymerase chain reaction assay that detects 7 mutations of the KRAS gene; tumors with none of these mutations are considered wild-type KRAS tumors.

*For PDFs of the full article and accompanying Commentary, click on the links to the left of this introduction.

Article PDF
Author and Disclosure Information

Publications
Topics
Legacy Keywords
colorectal cancer, cetuximab, FOLFIRI, KRAS
Author and Disclosure Information

Author and Disclosure Information

Article PDF
Article PDF


In July 2012, cetuximab was approved for use in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin) for first-line treatment of patients with KRAS mutation-negative (wild-type), EGFR-expressing metastatic colorectal cancer (mCRC) as determined by Food and Drug Administration-approved tests. A companion diagnostic, Therascreen KRAS RGQ PCR Kit for determining KRAS mutation status was approved concurrently with the cetuximab approval. The test is a real-time polymerase chain reaction assay that detects 7 mutations of the KRAS gene; tumors with none of these mutations are considered wild-type KRAS tumors.

*For PDFs of the full article and accompanying Commentary, click on the links to the left of this introduction.


In July 2012, cetuximab was approved for use in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin) for first-line treatment of patients with KRAS mutation-negative (wild-type), EGFR-expressing metastatic colorectal cancer (mCRC) as determined by Food and Drug Administration-approved tests. A companion diagnostic, Therascreen KRAS RGQ PCR Kit for determining KRAS mutation status was approved concurrently with the cetuximab approval. The test is a real-time polymerase chain reaction assay that detects 7 mutations of the KRAS gene; tumors with none of these mutations are considered wild-type KRAS tumors.

*For PDFs of the full article and accompanying Commentary, click on the links to the left of this introduction.

Publications
Publications
Topics
Article Type
Display Headline
Cetuximab plus FOLFIRI in first-line treatment of KRAS mutation-negative, EGFR-positive metastatic colorectal cancer
Display Headline
Cetuximab plus FOLFIRI in first-line treatment of KRAS mutation-negative, EGFR-positive metastatic colorectal cancer
Legacy Keywords
colorectal cancer, cetuximab, FOLFIRI, KRAS
Legacy Keywords
colorectal cancer, cetuximab, FOLFIRI, KRAS
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Carfilzomib and bortezomib therapy in patients with multiple myeloma

Article Type
Changed
Fri, 01/04/2019 - 11:06
Display Headline
Carfilzomib and bortezomib therapy in patients with multiple myeloma

In July 2012, carfilzomib was given accelerated approval by the Food and Drug Administration for the treatment of patients with multiple myeloma (MM) who have received at least 2 prior therapies including bortezomib and an immunomodulatory agent and have exhibited disease progression during or within 60 days of completing their last therapy. The approval was based on results of a single-arm, multicenter phase 2 trial of carfilzomib in patients with relapsed and refractory MM. As a condition of the accelerated approval, the manufacturer of the drug has to submit a final analysis of an ongoing phase 3 trial that compares carfilzomib plus lenalidomide plus low-dose dexamethasone with lenalidomide plus low-dose dexamethasone in patients with relapsed and refractory MM after 1 to 3 previous therapies. The primary end point of this trial is progression-free survival (PFS)...

*For a PDF of the full article and accompanying Commentaries, click on the links to the left of this introduction.

Article PDF
Author and Disclosure Information

Publications
Topics
Legacy Keywords
carfilzomib, bortezomib, multiple myeloma
Author and Disclosure Information

Author and Disclosure Information

Article PDF
Article PDF

In July 2012, carfilzomib was given accelerated approval by the Food and Drug Administration for the treatment of patients with multiple myeloma (MM) who have received at least 2 prior therapies including bortezomib and an immunomodulatory agent and have exhibited disease progression during or within 60 days of completing their last therapy. The approval was based on results of a single-arm, multicenter phase 2 trial of carfilzomib in patients with relapsed and refractory MM. As a condition of the accelerated approval, the manufacturer of the drug has to submit a final analysis of an ongoing phase 3 trial that compares carfilzomib plus lenalidomide plus low-dose dexamethasone with lenalidomide plus low-dose dexamethasone in patients with relapsed and refractory MM after 1 to 3 previous therapies. The primary end point of this trial is progression-free survival (PFS)...

*For a PDF of the full article and accompanying Commentaries, click on the links to the left of this introduction.

In July 2012, carfilzomib was given accelerated approval by the Food and Drug Administration for the treatment of patients with multiple myeloma (MM) who have received at least 2 prior therapies including bortezomib and an immunomodulatory agent and have exhibited disease progression during or within 60 days of completing their last therapy. The approval was based on results of a single-arm, multicenter phase 2 trial of carfilzomib in patients with relapsed and refractory MM. As a condition of the accelerated approval, the manufacturer of the drug has to submit a final analysis of an ongoing phase 3 trial that compares carfilzomib plus lenalidomide plus low-dose dexamethasone with lenalidomide plus low-dose dexamethasone in patients with relapsed and refractory MM after 1 to 3 previous therapies. The primary end point of this trial is progression-free survival (PFS)...

*For a PDF of the full article and accompanying Commentaries, click on the links to the left of this introduction.

Publications
Publications
Topics
Article Type
Display Headline
Carfilzomib and bortezomib therapy in patients with multiple myeloma
Display Headline
Carfilzomib and bortezomib therapy in patients with multiple myeloma
Legacy Keywords
carfilzomib, bortezomib, multiple myeloma
Legacy Keywords
carfilzomib, bortezomib, multiple myeloma
Article Source

PURLs Copyright

Inside the Article

Article PDF Media